A phase II study of cabozantinib and temozolomide in advanced progressive gastroenteropancreatic or lung neuroendocrine tumors (NETs)

被引：0
|
作者：
Clemente, O. [1 ]
Cives, M. [2 ]
Guerrera, L. P. [1 ]
Tornesello, M. L. [3 ]
Bracigliano, A. [4 ]
Lauricella, E. [5 ]
Ragno, A. [2 ]
Scarpati, G. Della Vittoria [1 ]
Starita, N. [3 ]
Picozzi, F. [1 ]
Barretta, M. L. [6 ]
Badalamenti, G. [2 ,7 ]
Cannella, L. [1 ]
Lastoria, S. [4 ]
Di Mauro, A. [8 ]
Porta, C. G. [2 ]
Tafuto, S. [1 ]
机构：
[1] Ist Nazl Tumori IRCCS Fdn G Pascale, Rare Tumors & Sarcomas Dept, Naples, Italy
[2] Azienda Osped Univ Consorziale Policlin Bari, Med Oncol Unit, Bari, Italy
[3] Ist Nazl Tumori IRCCS Fdn G Pascale, Unit Mol Biol & Viral Oncogenesis, Naples, Italy
[4] Ist Nazl Tumori IRCCS Fdn G Pascale, Nucl Med Unit, Naples, Italy
[5] Univ Bari Aldo Moro, Interdisciplinary Dept Med, Bari, Italy
[6] Ist Nazl Tumori IRCCS Fdn G Pascale, Dept Radiol, Naples, Italy
[7] AOU Policlin Paolo Giaccone, Dept Oncol, Palermo, Italy
[8] Ist Nazl Tumori IRCCS Fdn G Pascale, Unit Patol, Naples, Italy
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.220
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
212P
引用
收藏
页码：S93 / S93
页数：1
相关论文
共 50 条
  • [41] Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Closer Look at the Characteristics of These Diverse Tumors
    Pape, Ulrich-Frank
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (12) : 8 - 11
  • [42] Phase I/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors
    Komoto, Izumi
    Kokudo, Norihiro
    Aoki, Taku
    Morizane, Chigusa
    Ito, Tetsuhide
    Hashimoto, Takuya
    Kimura, Wataru
    Inoue, Naoya
    Hasegawa, Kiyoshi
    Kondo, Shunsuke
    Ueno, Hideki
    Igarashi, Hisato
    Oono, Takamasa
    Makuuchi, Masatoshi
    Takamoto, Takeshi
    Hirai, Ichiro
    Takeshita, Akiko
    Imamura, Masayuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (07) : 708 - 716
  • [43] Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors
    Chan, Jennifer A.
    Stuart, Keith
    Earle, Craig C.
    Clark, Jeffrey W.
    Bhargava, Pankaj
    Miksad, Rebecca
    Blaszkowsky, Lawrence
    Enzinger, Peter C.
    Meyerhardt, Jeffrey A.
    Zheng, Hui
    Fuchs, Charles S.
    Kulke, Matthew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (24) : 2963 - 2968
  • [44] Effect of different expression status of MGMT on the efficacy of temozolomide in gastroenteropancreatic neuroendocrine tumors
    Li, Y.
    Qi, Z. R.
    Tan, H.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 163 - 163
  • [45] Recurrent/progressive oligodendroglial tumors:: A phase II study with temozolomide as first line chemotherapy.
    Soffietti, R.
    Rudà, R.
    Guarneri, D.
    Laguzzi, E.
    Trevisan, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 73S - 73S
  • [46] Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms
    Al-Toubah, Taymeyah
    Morse, Brian
    Strosberg, Jonathan
    PANCREAS, 2020, 49 (03) : 461 - 462
  • [47] Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms
    Al-Toubah, Taymeyah
    Morse, Brian
    Strosberg, Jonathan
    ONCOLOGIST, 2020, 25 (01): : E48 - E52
  • [48] Phase I/II Study of Everolimus (RAD001) in Combination With Temozolomide (TMZ) in Patients With Advanced Pancreatic Neuroendocrine Tumors (NET)
    Kulke, Matthew H.
    Blaszkowsky, Lawrence
    Zhu, Andrew X.
    Florio, Sarah
    Regan, Eileen
    Ryan, David P.
    Chan, Jennifer A.
    PANCREAS, 2011, 40 (02) : 328 - 328
  • [49] A phase I/II study of the combination of temozolomide (TM) and pazopanib (PZ) in advanced pancreatic neuroendocrine tumors (PNETs) (NCT01465659).
    Bhave, Manali A.
    Kircher, Sheetal Mehta
    Kalyan, Aparna
    Berlin, Jordan
    Mulcahy, Mary Frances
    Cohen, Steven J.
    Denlinger, Crystal S.
    Chiorean, E. Gabriela
    Sahai, Vaibhav
    Zalupski, Mark
    Rademaker, Alfred
    Benson, Al Bowen
    Nimeiri, Halla
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] Phase II study of ibrutinib in advanced carcinoid and pancreatic neuroendocrine tumors.
    Al-Toubah, Taymeyah E.
    Valone, Tiffany
    Schell, Michael J.
    Strosberg, Jonathan R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345